Search Results

20 posts

Dimerix gains NMPA approval for IND, opening doors to global phase three tudy on FSGS Treatment

Dimerix (ASX:DXB) has secured approval from the Chinese NMPA Centre for Drug Evaluation (CDE) for its…

Dimerix secures $10.7m upfront payment from Advanz Pharma

Dimerix (ASX:DXB) has received an initial upfront payment of A$10.7 million as part of its licensing…
The Market Online Video

Dimerix (ASX:DXB) to pocket $2.8m in R&D tax incentive prepayment

Dimerix (ASX:DXB) is set to pocket $2.8 million as a prepayment of a research and development…
The Market Online Video

Dimerix (ASX:DXB) receives FDA approval to include teenagers in kidney disease study

Dimerix (ASX:DXB) has received the green light to include paediatric patients in its ACTION3 study of…
The Market Online Video

Dimerix (ASX:DX8) closes recruitment for COVID-19 study early

Dimerix (ASX:DX8) has closed recruitment for its DMX-200 COVID-19 study, led by CLARITY 2.0, early so…
The Market Online Video

Dimerix (ASX:DXB) submits new patent family application for DMX-700

Dimerix (ASX:DXB) has submitted a new patent family application for its flagship DMX-700 used to treat…
The Market Online Video

Dimerix’s (ASX:DXB) DMX-700 study shows significant 80pc reduction in lung injury

Dimerix (ASX:DXB) has released its pipeline program DMX-700 study results which indicated a significant 80 per…
The Market Online Video

Dimerix (ASX:DXB) closes recruitment for REMAP-CAP study

Dimerix (ASX:DXB) has formally closed recruitment of moderate state COVID-19 patients for REMAP-CAP's renin angiotensin system…
The Market Online Video

Dimerix (ASX:DXB) to launch new DXM-200 clinical trial for diabetic kidney disease

Dimerix (ASX:DXB) has partnered with the Australian Centre for Accelerating Diabetes Innovations (ACADI) to test its…
Dimerix (ASX:DXB) - Non Executive Chairman, James Williams

Dimerix (ASX:DXB) recruits first patient in phase 3 DMX-200 trial

Dimerix (ASX:DXB) has recruited the first patient to its ACTION3 phase 3 DMX-200 clinical trial in…
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

Dimerix (ASX:DXB) lands FDA approval for ACTION3 phase three clinical study

Dimerix (ASX:DXB) has received approval from the US Food and Drug Administration (FDA) to proceed with…
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

Dimerix (DXB) pauses COVID-19 study recruitment to assess safety concerns

Dimerix (ASX:DXB) pauses recruitment of COVID-19 patients with COVID-19 for its clinical study after safety issues…

Dimerix (ASX:DXB) hits DMX-200 milestone with European trial approval

Dimerix (ASX:DMX) receives approval in Europe for a clinicial trial of its drug DMX-200 in treating…
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

Dimerix (ASX:DXB) doses first patients in India for COVID-19 study

Biopharmaceutical company Dimerix (ASX:DXB) doses its first patients with its inflammatory disease treatment, DMX-200, in India.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

Dimerix (ASX:DXB) receives Australian ethics approval for COVID-19 study

Dimerix (ASX:DXB) receives Australian ethics approval for its phase three COVID-19 study, dubbed CLARITY 2.0.

DSMB recommends Dimerix (ASX:DXB) continues COVID-19 pneumonia study

Dimerix (ASX:DXB) has recruited 662 patients with COVID-19 pneumonia into its ACE2 renin angiotensin system (RAS)…
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (ASX:DXB) is granted Australian ethics and regulatory approval for its Phase 3 clinical trial in…

Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (ASX:DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of…
Dimerix (ASX:DXB) - Non Executive Chair, James Williams

Dimerix (ASX:DXB) completes oversubscribed SPP

Clinical-stage biopharmaceutical company Dimerix (ASX:DXB) has successfully completed its share purchase plan (SPP).
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

Dimerix’s (ASX:DXB) DMX-200 closer to COVID-19 study in India

The Indian regulatory agency has recommended Dimerix's (ASX:DXB) DMX-200 clinical study in COVID-19 patients be approved.